Article Text

Download PDFPDF

The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma
  1. Andrzej Stankiewicz1,
  2. Joanna Wierzbowska1,
  3. Anna Siemiątkowska1,
  4. Beata Fuksińska1,
  5. Jacek Robaszkiewicz1,
  6. Arkadiusz Zegadło2,
  7. Rita Ehrlich3,
  8. Brent Siesky3,
  9. Alon Harris3
  1. 1Department of Ophthalmology, Military Health Service Institute, Warsaw, Poland
  2. 2Department of Radiology, Military Health Service Institute, Warsaw, Poland
  3. 3Glaucoma Research Center, Indiana University School of Medicine, Indianapolis, USA
  1. Correspondence to Dr Joanna Wierzbowska, Department of Ophthalmology, Military Health Service Institute, 128 Szaserów Str, 04-141 Warsaw 44, Poland; joanna.wierzbowska{at}gmail.com

Abstract

Aims To assess the additive effect of dorzolamide hydrochloride 2% on the diurnal intraocular pressure (IOP) curve and retrobulbar haemodynamics in patients with primary open-angle glaucoma (POAG) treated with morning-dosed bimatoprost 0.03%.

Methods Twenty-five patients with POAG were evaluated in a prospective, single-masked study. After a 1 week run-in period with bimatoprost all patients were treated with bimatoprost dosed once in the morning for 1 month, after which dorzolamide was added twice daily for 2 months. Goldmann applanation IOP, arterial blood pressure (ABP) and heart rate were measured every 2 h for 24 h and diurnal ocular perfusion pressure (OPP) was calculated. Colour Doppler imaging (CDI) of the ophthalmic artery (OA) and the central retinal artery (CRA) was recorded five times daily. All measurements were taken after the two phases of treatment and were compared.

Results The mean baseline IOP was 14.8±3.5 mm Hg. Mean IOP following bimatoprost monotherapy (12.8±2.9 mm Hg) and after 2 months of dorzolamide adjunctive therapy (12.2±2.6 mm Hg) were not statistically significantly different (p=0.544). Only at the 4:00 h time point was IOP significantly reduced using the bimatoprost/dorzolamide combined treatment (p=0.013). The 24 h IOP fluctuations were lower when dorzolamide was added (6.0±2.3 mm Hg vs 4.6±1.5 mm Hg, p=0.0016). Repeated analysis of variance detected a significant decrease of vascular resistance in the OA (p=0.0167) with adjunctive dorzolamide treatment.

Conclusions The addition of dorzolamide to morning-dosed bimatoprost had an additive hypotensive effect only on the night-time IOP curve at 4:00 h and resulted in a lower IOP fluctuation. Dorzolamide added to bimatoprost may reduce vascular resistance in the OA.

  • Colour Doppler imaging
  • imaging
  • intraocular pressure
  • medical treatment
  • ocular perfusion pressure
  • primary open-angle glaucoma

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Funding Merck & Co., Inc. and an unrestricted grant from research to prevent blindness.

  • Competing interests AH has acted as a consultant for Pfizer, MSD and Allergan, and received research grants from Pfizer, MSD and Allergan.

  • Ethics approval This study was conducted with the approval of the Military Health Service Institute, Warsaw, Poland.

  • Provenance and peer review Not commissioned; externally peer reviewed.